PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Profound Medical Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.86−0.15 (-2.50%)
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Profound Medical Corp. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurring - non-capital | $1.61M | $2.47M | $2.30M | $4.07M | $1.56M | $1.80M | $2.69M | $2.65M | $1.46M | $1.44M | – | – | 64.9% | +3.3% |
| Capital equipment | $871.00K | $2.86M | $3.68M | $1.22M | $650.00K | $820.00K | $1.49M | $179.00K | $773.00K | – | – | – | 35.1% | +34.0% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.75M | $1.62M | $3.72M | $5.00M | $1.98M | $1.54M | $2.88M | $2.21M | $1.10M | $1.16M | – | – | 70.3% | -11.7% |
| Canada | $556.00K | $3.57M | $2.02M | $119.00K | $94.00K | $852.00K | $1.15M | $318.00K | $872.00K | $104.00K | – | – | 22.4% | +491.5% |
| Germany | $182.00K | $150.00K | $239.00K | $168.00K | $140.00K | $226.00K | $152.00K | $302.00K | $260.00K | $177.00K | – | – | 7.3% | +30.0% |
From the segment and revenue-disaggregation notes of Profound Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.